Diasorin SpA (DSRLF) reports a 4% revenue increase in Q2 2026, driven by a U.S. immunodiagnostics recovery and strong Liaison Plex traction, while navigating China declines and tariff headwinds.

Wondering if DiaSorin at €61.66 still reflects its true worth, or if the market is missing something you can spot before others do? The share price has seen a 5.8% gain over the last 7 days, alongside declines of 10.3% over the last 30 days, 9.9% year to date, and 33.0% over the past year, so recent moves may be changing how investors think about both risk and opportunity here. Recent coverage around DiaSorin has focused on its position in the Medical Equipment space and how sentiment has...

Despite revenue growth and strategic investments, Diasorin SpA (DSRLF) faces hurdles in China and the molecular diagnostics segment.

The consensus estimate for Q4 2025 revenue is $0.30 billion, and the earnings are expected to come in at $0.81 per share. The full year 2025's revenue is expected to be $1.20 billion, and the earnings are expected to be $3.40 per share. More detailed estimate data can be found on the Forecast page.

Despite headwinds in China and Europe, Diasorin SpA (FRA:34D) reports robust core business growth and strategic advancements in the US market.

Thinking about what to do with DiaSorin stock right now? You are definitely not alone. With the share price recently closing at 79.14, it is no surprise many investors are re-examining their positions. Over the past year, DiaSorin’s share price has slipped by 22.6%, and if you zoom out to five years, the drop grows to 50.9%. Even the past week and month have not offered much relief, with declines of 3.5% and 5.8% respectively. You might wonder if this is an opportunity, or if there is more...